Dacomitinib monohydrateProduct ingredient for Dacomitinib

Name
Dacomitinib monohydrate
Drug Entry
Dacomitinib

Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains.2

Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018.14 Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model1, although further investigations are needed.

Accession Number
DBSALT002510
Structure
Synonyms
Dacomitinib hydrate
External IDs
PF-00299804-03
UNII
5092U85G58
CAS Number
1042385-75-0
Weight
Average: 487.96
Monoisotopic: 487.1786456
Chemical Formula
C24H27ClFN5O3
InChI Key
BSPLGGCPNTZPIH-IPZCTEOASA-N
InChI
InChI=1S/C24H25ClFN5O2.H2O/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31;/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29);1H2/b6-5+;
IUPAC Name
(2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}-4-(piperidin-1-yl)but-2-enamide hydrate
SMILES
O.COC1=C(NC(=O)\C=C\CN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
ChemSpider
25991414
ChEMBL
CHEMBL2105719
Predicted Properties
PropertyValueSource
Water Solubility0.00874 mg/mLALOGPS
logP4.88ALOGPS
logP4.71Chemaxon
logS-4.7ALOGPS
pKa (Strongest Acidic)12.5Chemaxon
pKa (Strongest Basic)8.55Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area79.38 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity129.91 m3·mol-1Chemaxon
Polarizability49.06 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon